Medical 21

Medical 21 is a developing medical technology company dedicated to revolutionizing coronary artery bypass grafting (CABG). Our flagship product, the MAVERICS small-diameter synthetic regenerative graft, is an investigational medical device designed to replace autologous vessel harvesting. By reducing or eliminating the need for traditional vessel harvesting, MAVERICS can streamline the CABG surgical process and reduce the risk of patient complications associated with additional surgical incisions. MAVERICS has not been approved by the U.S. Food and Drug Administration (FDA) or any foreign regulatory agencies, and its safety and efficacy have not been established. Although CABG remains a critical treatment for coronary artery disease (CAD), we believe there is an urgent need for safer and more reliable vascular grafts to address the limitations of autologous vessels—such as inconsistent quality, limited availability, and complications related to vessel harvesting. The MAVERICS graft is specially designed to integrate with the patient’s own cells, promoting natural healing while avoiding foreign body rejection.